DUBLIN--(BUSINESS WIRE)--The "Market for Active Pharmaceutical Ingredients in Japan - Forecast and Analysis 2018" report has been added to ResearchAndMarkets.com's offering.
Japan is one of the biggest pharmaceutical markets in the world, and the industry is expected to keep growing at a moderate pace in the coming years. As the Japanese population grows older in comparison to other markets, the government has been responding to its aging population by easing several regulations and also introducing innovative new drugs into the market.
It is expected that the pharmaceutical market in Japan, worth just under USD 70 billion at the end of 2016, will cross USD 73 billion by 2021.
In 2017, the Japanese market for active pharmaceutical ingredients (APIs) was one of the biggest in terms of revenues and had a share of nearly 55% of the global API industry.
However, due to severe fluctuations in the Japanese currency against the US dollar as well as the high level of maturity evident in the Japanese pharmaceutical sector, it is expected that the market will grow at a slower than usual rate in the coming years.
- Allergan PLC
- Aurobindo Pharma
- BASF SE
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- Daiichi Sankyo Company Limited
- Dr. Reddy's Laboratories Limited
- Lupin Limited
- Medtronic PLC
- Mylan Inc.
- Novartis AG
- Pfizer Inc.
- Ranbaxy Laboratories
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited
Key Topics Covered
B. Introduction to Active Pharmaceutical Ingredients
C. Global Market for Active Pharmaceutical Ingredients (APIs)
D. Market for Active Pharmaceutical Ingredients (APIs) in Asia Pacific
E. Market for Active Pharmaceutical Ingredients (APIs) in Japan
F. API Market in Japan: Industry Segmentation
G. Major Industry Players
H. Glossary of Terms
I. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/research/jcpcnm/2018_market_for?w=4